Breast Cancer Clinical Trial
Official title:
Internet Use Among Women With Recurrent Breast Cancer
RATIONALE: Gathering information about patients with breast cancer over time may help
doctors learn more about a patient's use of the internet to find information about
treatment, symptom management, and emotional support.
PURPOSE: This clinical trial is studying internet use among women with recurrent metastatic
breast cancer.
OBJECTIVES:
- To document the proportion of women who use the internet to access treatment and
symptom management information and to seek emotional support after diagnosis of
metastatic recurrent breast cancer.
- To evaluate the association of treatment stage and effectiveness with internet use.
- To evaluate the association of individual differences in patients' demographics,
beliefs, emotional functioning, and social and professional support with internet use.
- To evaluate the association of patients' use of the internet to seek resources with
their beliefs, emotional functioning, and relationship functioning.
OUTLINE: Patients undergo assessments consisting of paper and pencil questionnaires at four
time points. The timing of these assessments is linked to the patient's treatment course and
her presumed need to access internet resources for information on cancer, treatment, symptom
management, and emotional support. Patients who discontinue regular care at the Cancer
Institute of New Jersey site during the course of the study may complete study assessments
through phone interviews conducted by a member of the study team.
Patients undergo a baseline survey prior to deciding on a treatment course for their newly
progressive disease. Patients complete the first part of the survey to provide information
on demographics, beliefs about cancer, mood states, somatic symptoms, and available
resources for cancer information and emotional support. Patients complete the second part of
the survey, if they have used the internet previously to obtain information and resources
about cancer or if they have received cancer information that someone else located on the
internet for them, which inquires about patients' internet use, any internet resources they
have received from family members, friends, or other people they know, and their own
evaluation of these internet resources. Patients undergo the second study assessment after
completion of the first course of treatment and prior to initiating course 2 (i.e., 3 to 4
weeks after initiating treatment). The third study assessment occurs within the first 2
weeks after the medical oncologist's first evaluation of treatment response (i.e., 6-9 weeks
after initiating treatment). The fourth assessment occurs after the medical oncologist's
second evaluation of the patient's response to treatment, following tumor re-staging.
Patients complete several questionnaires during these assessments to provide information
about personal characteristics (demographics, physical and psychological well-being, beliefs
about cancer and treatment, optimism), social and healthcare networks (perceived social
support, social network composition, beliefs about treatment team), and outcomes (use of
non-internet cancer information, use of the internet for cancer resources, use of
interactive technologies, communication with treatment team and family, evaluation of
internet resources).
The following information is extracted from the patients' medical record: stage and node
status at primary diagnosis, previous oncology surgeries, previous adjuvant treatments,
current menopausal status, treatment at time of recurrence, disease free interval, site(s)
of metastasis, and response to current treatment.
;
Primary Purpose: Health Services Research
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |